Back to Search
Start Over
Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease
- Source :
- Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022), Scientific Reports
- Publication Year :
- 2022
- Publisher :
- Springer Science and Business Media LLC, 2022.
-
Abstract
- There is a closely relationship between the development and progression of nonalcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) and obesity and diabetes. NAFLD fibrosis scores should be routinely used to rule out patients with advanced fibrosis. High scores may help identify patients at higher risk of all causes andliverrelated morbidity and mortality. The aim of this study was to investigate the association between exenatide and fibrosis scores. The effect of exenatide treatment on fibrosis scores was evaluated in type 2 diabetes mellitus (DM) patients with MAFLD. Evaluation was made of 50 patients with type 2 DM and MAFLD. The NFS, FIB4 and APRI scores were calculated before and after 6 months of treatment. After 6 months of exenatide treatment, the NFS and APRI scores were determined to have decreased significantly. Exenatide was observed to control blood glucose, reduce body weight and improve fibrosis scores in MAFLD patients with type 2 diabetes.
- Subjects :
- Adult
Blood Glucose
Liver Cirrhosis
Male
Time Factors
Science
Incretins
Article
Decision Support Techniques
Endocrinology
Non-alcoholic Fatty Liver Disease
Predictive Value of Tests
Weight Loss
Humans
Hypoglycemic Agents
Retrospective Studies
Multidisciplinary
Gastroenterology
Middle Aged
Treatment Outcome
Diabetes Mellitus, Type 2
Liver
Exenatide
Medicine
Female
Biomarkers
Subjects
Details
- ISSN :
- 20452322
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....67ea48a027c98c78311a348f8a02c3c0